Trial Profile
A phase 3 study of ATL1103 in patients with acromegaly
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 10 Sep 2015
Price :
$35
*
At a glance
- Drugs Atesidorsen (Primary)
- Indications Acromegaly
- Focus Adverse reactions
- 10 Sep 2015 New trial record
- 09 Sep 2015 According to Antisense Therapeutics media release, company is planning for a pre-IND meeting with the FDA in the second half of 2015 to discuss about the requirements to initiate this trial.